Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KMO | O15229 | 2/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2753599 | 0.82 | CTSS (0.41) | ARCTSSCTSKGAAMAPK1 | |
| SCHEMBL6050957 | 0.79 | KDM4E (0.51) | IDO1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL468050 | 0.79 | KIF11 (0.50) | CTSSCTSKKDM4EALDH1A1MEN1 | |
| SCHEMBL17625946 | 0.78 | CTSS (0.48) | CTSSCTSKXDHADORA2AADORA1 | |
| SCHEMBL17625956 | 0.77 | RXRA (0.37) | CTSSCTSKTDP1 | |
| SCHEMBL2751038 | 0.77 | NOTUM (0.47) | CTSSCTSKKMONOTUM | |
| SCHEMBL1915009 | 0.76 | IDO1 (0.45) | IDO1CTSSCTSKRAB9AKDM4E | |
| SCHEMBL468087 | 0.76 | CYP19A1 (0.45) | IDO1CTSSCTSKGAAMAPK1 | |
| SCHEMBL7228532 | 0.76 | RAB9A (0.51) | IDO1CTSSCTSKGAARAB9A | |
| SCHEMBL4711911 | 0.76 | RECQL (0.50) | GAARAB9AKDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100464742-C | NF-kB activation inhibitor | INST MED MOLECULAR DESIGN INC (JP) | 2009-03-04 | — | — | CN | claimed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | claimed |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) | 2008-09-25 | — | — | US | claimed |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-06-08 | — | — | US | disclosed |
| US-11555037-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-01-17 | — | — | US | disclosed |
| CN-109776537-B | Purine diones as WNT pathway modulators | 新加坡科技研究局 | 2021-12-14 | — | — | CN | disclosed |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-27 | — | — | US | disclosed |
| US-10844063-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-11-24 | — | — | US | disclosed |
| US-20200190086-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-06-18 | — | — | US | disclosed |
| EP-2999699-B1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY SCIENCE TECH & RES (SG) | 2020-04-29 | — | — | EP | disclosed |
| US-10472360-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-11-12 | — | — | US | disclosed |
| CN-1658856-A | Cancer therapeutic agent | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| EP-1555018-A1 | REMEDIES FOR NEURODEGENERATIVE DISEASES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1535610-A1 | THERAPEUTIC AGENT FOR CANCER | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1535609-A1 | NF-KB ACTIVATION INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-6605631-B1 | Controlling fungi and pests; improved activity and plant tolerability | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | NFKBIA, IKBKB, RELA | IDO1 3169/4885AR 4190/4885CTSS 2160/4885 |
| US-10472360-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, CTNNB1 | IDO1 520/4885AR 281/4885CTSS 4477/4885 |
| US-11555037-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, WNT3 | IDO1 541/4885AR 139/4885CTSS 4450/4885 |
| US-20200190086-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, CTNNB1 | IDO1 520/4885AR 281/4885CTSS 4477/4885 |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MAPT, TFEB, MAOA | IDO1 3097/4885AR 1316/4885CTSS 500/4885 |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | IDO1 541/4885AR 139/4885CTSS 4450/4885 |
| US-10844063-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, CTNNB1 | IDO1 520/4885AR 281/4885CTSS 4477/4885 |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | IDO1 541/4885AR 139/4885CTSS 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.